AzTrials
AzTrials

Pelvic Floor DisordersNCT04826939

Intravaginal Devices for Pelvic Floor Motion

A study testing PFDx device and leva device in people with Pelvic Floor Disorders, run by University of Oklahoma at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The leva and PFDx devices accurately reflect pelvic floor motion consistent with TPUS evaluation. During a voluntary PFM contraction, the change in angle from a position of rest to maximal effort that is detected by each device is positively correlated with TPUS measurements and Modified Oxford scores. Read more about this study

Who is it for?
Ages 18 to 100 years, women onlyHealthy volunteers can take part
Conditions the study is for
Pelvic Floor Disorders
What is being tested?
PFDx device and leva device
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
2 sitesUnited States
Study dates
25 Mar 2021to 26 Sep 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Female
  • 18 years of age or older
  • Presence of a vagina
  • Ability to read and write English
  • BMI <30
  • Reports they are able to perform a kegel exercise

Who cannot join

  • Inability to perform a kegel exercise
  • Pelvic organ prolapse greater than ICS POP-Q Stage II
  • Known, untreated pelvic, vaginal or urinary tract infection
  • Currently pregnant

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • OU Physicians

    Oklahoma City, Oklahoma, 73104

  • University ofOklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73104

Other trials in United States

About this study

Official title: Validity (and Reliability) of Two Forms of an Accelerometer-Based Intravaginal Device for Detecting Pelvic Floor Motion

The leva and PFDx devices accurately reflect pelvic floor motion consistent with TPUS evaluation. During a voluntary PFM contraction, the change in angle from a position of rest to maximal effort that is detected by each device is positively correlated with TPUS measurements and Modified Oxford scores.

Read the detailed description

Thirty women 18 years or older will be recruited from OB/GYN, FPMRS or other clinics. Following informed consent and successful screening, subjects will undergo testing as outlined below. Five subjects (all will be invited until five subjects have agreed) will return to clinic in 1-2 weeks to undergo repeat testing using all modalities.

After obtaining informed consent, subject information will be collected, including demographic data, BMI, and medical history (including ob/gyn history). Subjects will complete urinalysis for pregnancy. Subjects will also complete the Pelvic Floor Distress Inventory (PFDI-20) questionnaire. All subjects will undergo a complete pelvic examination including pelvic organ prolapse quantification (POP-Q), a digital assessment of PFM strength (Modified Oxford Scale) and receive a TPUS. Subjects will also complete a series of PFM contractions using the leva and PFDx devices to measure angle changes, and undergo vaginal assessment with a perineomter.

Pelvic floor muscle assessment Prior to recording device measurements, a correct pelvic floor muscle contraction will be verified via manual pelvic floor assessment. Subjects will be instructed to perform a "lift-and-squeeze" maneuver of the pelvic floor, and correct PFM contraction will be verified by the primary examiner (LHQ). PFM strength will then be assessed via digital palpation by the examiner inserting the first and/or second fingers approximately 4 cm into the vagina and palpating the right and left PFM during contraction. Strength will be graded according to the 6-point Modified Oxford Scale (0=no contraction; 1='flicker'; 2=weak; 3=moderate; 4=good; 5=strong). The mean score of the right and left sides of the vagina will be calculated and used for correlation analysis.

Perineometry PFM strength will be measured using a Peritron™ perineometer, which is a 28mm diameter compressible probe connected to a handheld microprocessor. It provides readings of pelvic floor contraction in cm of H20 with precision up to one decimal point, and it has been demonstrated to show reproducible and reliable measurements. The resting vaginal pressure and two peak pressures will be measured. For this study, PFM strength is defined as the augmented vaginal pressure, calculated by measuring the average of 2 peak pressures minus the resting vaginal pressure.

TPUS measurements TPUS imaging will be completed at the time of the study visit using the BK Medical Ultrafocus (Peabody, MA) and 8802 transperineal transducer. The probe will be covered with ultrasound gel and a probe cover. All ultrasound studies will be performed in the office setting with the patient in the dorsal lithotomy position, with hips flexed and abducted. No preparation is required, and no rectal or vaginal contrast will be used. Patients will be instructed to arrive at the office with a partially full bladder and to avoid excessive pressure on surrounding structures that might distort the anatomy. In the sagittal view, dynamic ultrasound parameters will be measured relative to a horizontal reference line at the level of the infero-posterior margin of the pubic symphysis. Dynamic images will be obtained during PFM contractions and at rest. At least 3 cycles of PFM contraction and relaxation will be recorded for each individual.

Baseline assessment will be performed at rest, then with 3 maximum-effort voluntary contraction (MVC). Ultrasound measurements will include: Anterior-posterior distance (APD) of the levator hiatus to the pubic bone (primary aim), levator urethra gap (LUG), distance from bladder neck to the pubic bone and distance of the midurethra to the pubic bone. Urethral angle at rest and with max contraction will also be measured. The cravioventral shift of the levator plate relative to a vertical line of reference relative to the anorectal angle will also be measured.

Leva measurements Subjects will be instructed on proper insertion and placement of the leva device. The examiner will assist with device placement, as needed. With the leva inserted, subjects will assume a standing position. Subjects will complete a series of pelvic floor muscle training (five lifts for 15 seconds of maximum lift, followe by 15 seconds of rest).

PFDx measurements The examiner will place the PFDx in the vagina, ensuring the ring component is positioned at the fornix with the extension running the length of vagina and out of the body. With the device retained in the vagina, subjects will assume a standing position. Angle measurements will be recorded at rest and with maximal voluntary 'lift-and-squeeze' contraction. These measurements will be repeated at least 3 times with 1-minute rest between each measurement.

Being tested
PFDx device and leva device
Medical subject headings
Pelvic Floor Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PFDx device and leva deviceDevice

    Participants will use the leva device, PFDx device and undergo ultrasound measurements during pelvic floor motion to compare the three measurements.

Study groups in NCT04826939
Study groupRoleWhat they receive
Device usageExperimentalAll participants will complete a survey and undergo an evaluation to test the movement of their pelvic floor with the PFDx device and leva device
Receives: Device: PFDx device and leva device

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Validate leva measurements with transperineal ultrasound (TPUS)

    During a voluntary pelvic floor muscle contraction, the change in angle from a position of rest to maximal effort that is detected by the leva device will be compared to the change in distance from the pubic bone to the levator plate measured by 2D TPUS during the same task.

    Measured: Through final study visit (about 3 months)

Secondary outcomes (9)
  1. Compare leva angle change measurements with Modified Oxford, Brinks

    Modified Oxford, Brinks is a commonly used clinical assessment tool to measure pelvic floor muscle strength

    Measured: Through final study visit (about 3 months)

  2. Compare PFDx angle change measurements with Modified Oxford, Brinks

    Modified Oxford, Brinks is a commonly used clinical assessment tool to measure pelvic floor muscle strength

    Measured: Through final study visit (about 3 months)

  3. Compare PFDx to a perineometer

    Measuring angle change measurements with change in vaginal squeeze pressure

    Measured: Through final study visit (about 3 months)

  4. Compare leva to a perineometer

    Measuring angle change measurements with change in vaginal squeeze pressure

    Measured: Through final study visit (about 3 months)

  5. Determine the test-retest reliability of Manual muscle testing angle measurements over 2 time points

    Time points are 1-2 weeks apart

    Measured: Through final study visit (about 3 months)

  6. Determine the test-retest reliability of perineometry angle measurements over 2 time points

    Time points are 1-2 weeks apart

    Measured: Through final study visit (about 3 months)

  7. Determine the test-retest reliability of ultrasound angle measurements over 2 time points

    Time points are 1-2 weeks apart

    Measured: Through final study visit (about 3 months)

  8. Determine the test-retest reliability of leva angle measurements over 2 time points

    Time points are 1-2 weeks apart

    Measured: Through final study visit (about 3 months)

  9. Determine the test-retest reliability of PFDx angle measurements over 2 time points

    Time points are 1-2 weeks apart

    Measured: Through final study visit (about 3 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Apr 2021
  2. Study start25 Mar 2021
  3. Primary completion26 Sep 2022
  4. Study completion26 Sep 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04826939
Sponsor's protocol ID
13114
Status last verified
Jun 2023
First submitted
4 Mar 2021
Last updated
13 Jun 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No: No plans to share information

Questions about this trial

What is this clinical trial studying?

A study testing PFDx device and leva device in people with Pelvic Floor Disorders, run by University of Oklahoma at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Validate leva measurements with transperineal ultrasound (TPUS) (time frame: Through final study visit (about 3 months)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jun 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in